Listen in the Podli app 🎧
Follow your favourite podcasts, listen offline and in the car with CarPlay and Android Auto, and always pick up where you left off. Free to try.
Featuring an interview with Dr Douglas W Sborov, including the following topics:
- DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00)
- Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for relapsed/refractory MM (4:26)
- Progression-free survival estimates with current quadruplet induction and maintenance regimens for newly diagnosed MM (6:36)
- Phase I DREAMM-9 trial and ongoing evaluation of belamaf in the up-front setting (11:48)
- Potential integration of belamaf into the relapsed/refractory and newly diagnosed MM treatment settings (16:00)
- Prevention and management of ophthalmic events related to treatment with belamaf (21:27)
- Case: A man in his mid 60s with multiregimen-recurrent MM receives single-agent belamaf (27:49)
- Case: A woman in her early 70s with recurrent t(11;14) MM and disease progression on single-agent belamaf experiences a sustained response to talquetamab (33:27)
- Case: A man in his early 70s with heavily pretreated MM receives belamaf with bortezomib (39:53)
CME information and select publications
